Last reviewed · How we verify
NCT04512573
Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)
trial in Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER) in 232 participants. Completed in 31 August 2022.
31 August 2022
Quick facts
| Lead sponsor | CorEvitas |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 232 |
| Start date | 21 May 2020 |
| Primary completion | 31 August 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across United States |
Conditions studied
- Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER) — all drugs for Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER) →
Sponsor
CorEvitas — full company profile →
Who can join
Adults 18 to 99, any sex, with Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, real-world observational study in which patients with RA who are initiating treatment with a JAK inhibitor medication will self-report disease activity and treatment satisfaction measures using their own web-enabled device such as a smartphone. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Tokareva K, Reid P, Yang V, Liew D, et al · · 2023 · cited 20× · PMID 37596779 · DOI 10.1080/1744666x.2023.2249237
Verify or expand the search:
- PubMed search for NCT04512573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other CorEvitas trials
Trials by the same sponsor.
- NCT07420075 — Alzheimer's Registry · enrolling by invitation
- NCT07217509 — PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry · enrolling by invitation
- NCT06804057 — CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry · recruiting
- NCT06521944 — RSV Vaccine Pregnancy Registry · recruiting
- NCT06562270 — CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04512573 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CorEvitas
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04512573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing